FREMONT, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. BTIG 12th Annual MedTech, Digital …
JOHANNESBURG, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) today released results for the second quarter of fiscal 2025 (“Q2 2025”). Q2 2025 performance: Revenue of $146.8 million (ZAR 2.6 billion) was at the upper …
Third Quarter Financial Highlights: • Increased Revenue by 56% Year Over Year to Above $60 Million • Net Income of over $2 Million • Generated nearly $6 Million of Operating Cash Flow Company to host conference call tomorrow, February 6, at 10:00 am ET …
REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the …
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products …
LAKE FOREST, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- ATIF Holdings Limited (Nasdaq: ZBAI) (the “Company”), a Lake Forest-based business consulting company that specializes in providing professional IPO, M&A advisory and post-IPO compliance services …
Enhanced liquidity by $27.5 million through the issuance of 6.9 million common shares First quarter fiscal 2025 revenue declined 11.5% to $119.9 million Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Feb. 05, 2025 (GLOBE NEWSWIRE) …
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its …
FOSTER CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases …
LEHI, Utah, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (Nature's Sunshine) (NASDAQ: NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the appointment of Ms. Katie A. May to its …
Revenue up 12% Year-Over-Year Fourth Consecutive Quarter of Double-Digit Revenue Growth Fiscal YTD Operating Cash Flow up 17% Year-Over-Year SAN FRANCISCO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- LiveRamp® (NYSE: RAMP), the leading data collaboration platform, …
- Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration - - RT-116 was well tolerated with no serious adverse events - - Data adds to growing …
TORONTO and HAIFA, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is pleased to announce the formation of a U.S.-based subsidiary, Exo-Top Inc. (“Exo-Top”), that is …
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight and …
BOULDER, Colo., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Gaia, Inc. (NASDAQ: GAIA) (“Gaia” or the “Company”), a conscious media and community company, announced today that it intends to offer and sell shares of its Class A common stock in an underwritten public …
BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, …
– KOMET-001 registrational trial in R/R NPM1-m AML achieved primary CR/CRh endpoint; topline data submitted for presentation at an upcoming medical meeting – – NDA submission for ziftomenib on track for 2Q 2025 – – Registrational KOMET-017-IC trial of …
FY24 revenue of $764 million, up 15.2% from $663 million in FY23, driven by growth in HBM revenue; Announces acquisition of minority interest in FICT Limited, a key supplier of industry-leading, high-performance advanced probe card components LIVERMORE, …
COPENHAGEN, Denmark, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2024 financial results and provide a business update on Wednesday, February 12, 2025, after the close of the U.S. financial …
Super Bowl LIX is projected to shatter betting records as regulated US sportsbooks are estimating $1.5 billion in legal wagers nationwide. LAS VEGAS, NV, UNITED STATES, February 5, 2025 /EINPresswire.com/ -- Bettors are on target to place a record- …
